Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis
Objective: We evaluated both the efficacy and safety of anakinra in daily routine rheumatoid arthritis clinical practice. Methods:We studied 60 cases, including patients with previous anti-TNFα exposure, treated with anakinra (100 mg/daily s.c.) in combination with methotrexate (7.5-10 mg/week i.m.)...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
PAGEPress Publications,
2011-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_5d0e3d11f15e4cd88cdf87bb19fe026f | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a S. Todesco |e author |
| 700 | 1 | 0 | |a U. Fiocco |e author |
| 700 | 1 | 0 | |a M. Biscaro |e author |
| 700 | 1 | 0 | |a P. Ostuni |e author |
| 700 | 1 | 0 | |a A. Furlan |e author |
| 700 | 1 | 0 | |a P. Sfriso |e author |
| 700 | 1 | 0 | |a C. Botsios |e author |
| 700 | 1 | 0 | |a L. Punzi |e author |
| 245 | 0 | 0 | |a Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis |
| 260 | |b PAGEPress Publications, |c 2011-09-01T00:00:00Z. | ||
| 500 | |a 10.4081/reumatismo.2007.32 | ||
| 500 | |a 0048-7449 | ||
| 500 | |a 2240-2683 | ||
| 520 | |a Objective: We evaluated both the efficacy and safety of anakinra in daily routine rheumatoid arthritis clinical practice. Methods:We studied 60 cases, including patients with previous anti-TNFα exposure, treated with anakinra (100 mg/daily s.c.) in combination with methotrexate (7.5-10 mg/week i.m.) or leflunomide (20 mg/die) in a two year observational study. Efficacy measures were assessed using the American College of Rheumatology (ACR) response criteria. Safety was evaluated according to a modified World Health Organization adverse reaction term dictionary. Results: At week 14, ACR 20% response criteria have been fulfilled by 53 (91.3%) out of 58 patients, 51 (87.9%) of them achieving also an ACR 50%and 15 (25.8%) an ACR 70%response. Thirteen patients touched 102 weeks of treatment: ACR 20% response was achieved in 92.3%, while ACR 50% and ACR 70% were respectively found in 84.6% and 38.4% of the cases. The mean decrease in HAQ score was 0.38, p<0.001. Of the 16 patients who were previously treated with anti-TNFα blockers, 81.2% responded to anakinra. There was no significant difference in the ACR response between groups with and without previous anti-TNFα exposure. Seventeen patients (28.3%) stopped anakinra because of side-effects (5%) or failure to respond (23.3%). Only 4 cases of pulmonitis, of which 2 have been hospitalised, and 1 case with tuberculosis (previously treated with infliximab) were observed. Conclusions: Our clinical experience confirms that anakinra is effective and safe in the treatment of rheumatoid arthritis. Anakinra seems also useful in patients with previous anti-TNFα blockers failures. Even though major adverse events were rare, clinicians should be aware of such a possibility | ||
| 546 | |a EN | ||
| 546 | |a IT | ||
| 690 | |a Medicine | ||
| 690 | |a R | ||
| 690 | |a Internal medicine | ||
| 690 | |a RC31-1245 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Reumatismo, Vol 59, Iss 1, Pp 32-37 (2011) | |
| 787 | 0 | |n http://www.reumatismo.org/index.php/reuma/article/view/293 | |
| 787 | 0 | |n https://doaj.org/toc/0048-7449 | |
| 787 | 0 | |n https://doaj.org/toc/2240-2683 | |
| 856 | 4 | 1 | |u https://doaj.org/article/5d0e3d11f15e4cd88cdf87bb19fe026f |z Connect to this object online. |